The long-term effect of treatment with interferon-α2a in chronic hepatitis B

Journal of Viral Hepatitis

Volumn 5, Issue 6, 1998, Pages 389-397

  Krogsgaard, Kim ^a,s   Thomas, H C ^b   Farrell, G ^c   Cooksley, W G E ^d   Moroni, M ^e   Carreno, V ^f   Perez, V ^g   Realdi, G ^h   Hess, G ⁱ   Lok, A S F ^j   Tanno, H ^k   Pastore, G ^l   Hiltbrunner, V ^m   Ryff, J Charles ^m   Schmid, E ^m   Smith, P ^m   Andersen, P K ^a   Bindslev, N ^a   Craxi, A ⁿ   Christensen, E ^o   Ring Larsen, H ^p   Schlichting, P ^a   Schalm, S ^q   Trepo, C ^r   more..

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF MILAN   (Italy)

^f Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^g HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^h UNIVERSITY OF SASSARI   (Italy)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

^j UNIVERSITY OF HONG KONG   (Hong Kong)

^k UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^l POLICLINICO   (Italy)

^m Hoffman la Roche ^*  (Switzerland)

ⁿ VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^o BISPEBJERG HOSPITAL   (Denmark)

^p Rigshospitalet   (Denmark)

^q ERASMUS MEDICAL CENTER   (Netherlands)

^r HÔTEL DIEU   (France)

^s HVIDOVRE HOSPITAL   (Denmark)

more..

Author keywords

Antiviral treatment; Chronic hepatitis B; Follow up study; Interferon 2a; Randomized controlled trials

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0031769390     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1998.00118.x     Document Type: Article

References (19)

1. Hoofnagle JH, Peters M, Mullen KG et al. Randomized, controlled trial of recombinant human alfa-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95:1318-1325.
2. Brook MG, McDonald JA, Karayiannis P et al. Randomized controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 1989; 30: 1116-1122.
3. Saracco G, Mazzella G, Rosina F et al. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology 1989; 10: 336-341.
4. Brook GM, Chan, Yap I et al. Randomized controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. BMJ 1989; 299: 652-656.
5. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effects of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A metaanalysis. Ann Intern Med 1993; 119: 312-323.
6. Carreno V, Castillo I, Molina J, Porres JC, Bartolome J. Long-term follow-up of heaptitis B chronic carriers who responded to interferon therapy. J Hepatol 1992; 15: 102-106.
7. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 629-634.
8. Hope RL, Weltman M, Dingley J et al. Interferon alfa for chronic active hepatitis B. Long-term follow-up of 62 patients: outcomes and predictors of response. Med J Aust 1995; 162: 8-11.
9. Lok ASF, Chung HT, Liu VWS, Ma OCK. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105: 1833-1838.
10. Nordenfeldt E, Kjellen L. Dane particles, DNA polymerase and e antigen in two distinct categories of heaptitis B antigen carriers. Intervirology 1975; 5: 225-232.
11. Hoofnagle JH, Dusheiko GM, Seff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94: 744-748.
12. Realdi G, Alberti A, Rugge M et al. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 1980; 79: 195-199.
13. Realdi G, Fattovich G, Hadziyannis S et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994; 21: 656-666.
14. de Jongh FE, Janssen HLA, de Man RA, Hop WCJ, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-1635.
15. Thomas HC, Lok ASF, Carreno V et al. Comparative study of three doses of interferon-α2a in chronic active hepatitis B. J Viral Hep 1994; 1: 139-148.
16. Realdi G, Fattovich G, Pastore G et al. Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study. J Hepatol 1990; 11: 8129-8132.
17. Ryff JC. To treat or not to treat? The judicious use of interferon alfa-2a for the treatment of chronic hepatitis B. J Hepatol 1993; 17: S42-S46.
18. Fattovich G, Brollo L, Giustina G et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-298.
19. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427.